| Accession Number: | 0001209191-20-026231 |
| Date: | 2020-04-27 |
| Issuer: | ADAPTIVE BIOTECHNOLOGIES CORP (ADPT) |
| Original Submission Date: |
TAYLOR STACY L
C/O ADAPTIVE BIOTECHNOLOGIES
1551 EASTLAKE AVE E STE 200
SEATTLE, WA 98102
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|---|---|---|---|---|---|---|---|---|
| COMMON STOCK | 2020-04-27 | M | 8,310 | a | $7.80 | 9,610 | direct | ||
| COMMON STOCK | 2020-04-27 | M | 11,270 | a | $6.55 | 20,880 | direct | ||
| COMMON STOCK | 2020-04-27 | S | 19,580 | d | $30.22 | 1,300 | direct |
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY) | 7.8 | 2020-04-27 | deemed execution date | M | 8,310 (d) | 2029-04-23 | common stock 8,310 | $7.80 | 41,690 | direct | ||
| STOCK OPTION (RIGHT TO BUY) | 6.55 | 2020-04-27 | deemed execution date | M | 11,270 (d) | 2028-04-24 | common stock 11,270 | $6.55 | 40,730 | direct |
| ID | footnote |
|---|---|
| f1 | the transactions reported in this form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on november 22, 2019. |
| f2 | the price reported for this transaction is a weighted-average price. the shares were sold in multiple transactions ranging from $30.00 to 30.51, inclusive. the reporting person undertakes to provide to adaptive biotechnologies corporation, any security holder of adaptive biotechnologies corporation, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this form 4. |
| f3 | the options vested with respect to 1/4 of such shares on april 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
| f4 | the options vested with respect to 1/4 of such shares on march 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
